GLP-1: Broadening the incretin concept to involve gut motility

Regulatory Peptides

Volumn 156, Issue 1-3, 2009, Pages 9-12

  Hellström, Per M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glucagon like peptide 1; Incretin; Irritable bowel syndrome; L cell; Motility

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN; PLACEBO; ROSE 010; UNCLASSIFIED DRUG;

ANALGESIA; APPETITE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MEGADOSE; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRACT FUNCTION; HUMAN; INSULIN RELEASE; INTESTINE MOTILITY; IRRITABLE COLON; LOW DRUG DOSE; MIGRATING MYOELECTRIC COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SMALL INTESTINE; SMOOTH MUSCLE RELAXATION; STOMACH EMPTYING; STOMACH MOTILITY; WEIGHT REDUCTION;

ANIMALS; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; IRRITABLE BOWEL SYNDROME;

ANIMALIA; RATTUS;

EID: 67449152255     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.04.004     Document Type: Review

References (23)

1. Gutniak M.K., Juntti-Berggren L., Hellström P.M., Guenifi A., Holst J.J., and Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19 (1996) 857-863
2. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Ørskov C., Ritzel R., and Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997) E981-E988
3. Gutniak M.K., Svartberg J., Hellström P.M., Holst J.J., Adner N., and Ahrén B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 250 (2001) 81-87
4. Meier J.J., Kemmeries G., Holst J.J., and Nauck M.A. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54 (2005) 2212-2218
5. Näslund E., Bogefors J., Grybäck P., Bjellerup P., Jacobsson H., Holst J.J., and Hellström P.M. GLP-1 inhibits gastric emptying of water but does not influence plasma. Scand J Gastroenterol 36 (2001) 156-162
6. Näslund E., Bogefors J., Skogar S., Grybäck P., Jacobsson H., Holst J.J., and Hellström P.M. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277 (1999) R910-R916
7. Schirra J., Wank U., Arnold R., Göke B., and Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50 (2002) 341-348
8. Meier J.J., Gallwitz B., Salmen S., Goetze O., Holst J.J., Schmidt W.E., and Nauck M.A. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 2719-2725
9. Wishart J.M., Horowitz M., Morris H.A., Jones K.L., and Nauck M.A. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 19 (1998) 1049-1053
10. Andrews C.N., Bharucha A.E., Camilleri M., Low P.A., Seide B.M., Burton D.D., Nickander K.K., Baxter K.L., and Zinsmeister A.R. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. Neurogastroenterol Motil 19 (2007) 716-723
11. Näslund E., Gutniak M., Skogar S., Rössner S., and Hellström P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68 (1998) 525-530
12. Näslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., Rössner S., and Hellström P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
13. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
14. Flint A., Raben A., Ersbøll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25 (2001) 781-792
15. Verdich C., Flint A., Gutzwiller J.P., Näslund E., Beglinger C., Hellström P.M., Long S.J., Morgan L.M., Holst J.J., and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (2001) 4382-4389
16. Näslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., and Hellström P.M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 91 (2004) 439-446
17. Pi-Sunyer F.X. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 120 (2008) 5-17
18. Tolessa T., Gutniak M., Holst J.J., Efendic S., and Hellström P.M. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 102 (1998) 764-774
19. Tolessa T., Gutniak M., Holst J.J., Efendic S., and Hellström P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43 (1998) 2284-2290
20. Näslund E., Skogar S., Efendic S., and Hellström P.M. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept 106 (2002) 89-95
21. Hellström P.M., Näslund E., Edholm T., Schmidt P.T., Kristensen J., Theodorsson E., Holst J.J., and Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 20 (2008) 649-659
22. Bucinskaite V., Tolessa T., Pedersen J., Rydqvist B., Legesse Z., Holst J.J., and Hellström P.M. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil (2009) [Electronic publication ahead of print]
23. Hellström P.M., Hein J., Bytzer P., Björnsson E., Kristensen J., and Schambye H. Clinical trial: The GLP-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomised, placebo-controlled, double-blind study. Aliment Pharmacol Ther 29 (2009) 198-206